Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Ricardo L B CostaHyo Sook HanWilliam J GradisharPublished in: Breast cancer research and treatment (2018)
The development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways.